ARDX * Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ardelyx, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$110.00 |
| 52 Week High | US$140.00 |
| 52 Week Low | US$63.70 |
| Beta | 0.89 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARDX * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how ARDX * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how ARDX * performed against the MX Market.
Price Volatility
| ARDX * volatility | |
|---|---|
| ARDX * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: ARDX * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ARDX *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 267 | Mike Raab | www.ardelyx.com |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder.
Ardelyx, Inc. Fundamentals Summary
| ARDX * fundamental statistics | |
|---|---|
| Market cap | Mex$27.62b |
| Earnings (TTM) | -Mex$1.24b |
| Revenue (TTM) | Mex$4.01b |
6.9x
P/S Ratio-22.2x
P/E RatioIs ARDX * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARDX * income statement (TTM) | |
|---|---|
| Revenue | US$210.00m |
| Cost of Revenue | US$70.84m |
| Gross Profit | US$139.16m |
| Other Expenses | US$204.31m |
| Earnings | -US$65.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 66.27% |
| Net Profit Margin | -31.02% |
| Debt/Equity Ratio | 83.9% |
How did ARDX * perform over the long term?
See historical performance and comparison